Bixiye
QP82-23 Commercial Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Izervay™, and Veopoz™
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 991 - 1000 ee natiijooyinka 3604
Bixiye
QP83-23 Commercial Pharmacy Benefit Exclusion for Budesonide-Formoterol Aerosol Inhaler and Tiotropium Bromide Inhalation Capsule
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP84-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP85-23 MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP86-23 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective November 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP87-23 Availity Essentials Updated Claim Entry Forms
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Warqada dawada ee dhakhtar qoray & farmashiye
Bixiye
policyii-174-med-drug-eval-process-list-2023-1001.pdf
Warqada dawada ee dhakhtar qoray & farmashiye
Bixiye
bc-com-med-adv-preferred-drug-list-2023-1002.pdf
Bixiye
P67-23 Expansion of the Peer Specialist Benefit
Taariikhda uu dhaqangalayo barnaamijka: Okt 02, 2023